Shots:
- Wave to receive $22.5M for research & preclinical expenses and is eligible to receive opt-in payment, development & commercial milestone & will lead the manufacturing & joint clinical co-development activities. Both companies will share global costs & 50:50 profits
- Takeda’s gets an option to co-develop & co-commercialize CNS therapies for 3 targets, C9orf72, HTT & ATXN3, including WVE-004/003 & will lead the joint co-commercial activities in the US & all commercial activities outside of the US
- Takeda discontinues its discovery research with Wave for CNS programs & Takeda gets the right to license multiple preclinical programs for CNS indications over 4 yrs. research term
Click here to read the full press release/ article | Ref: Globe Newswire | Image: GeneOnline
The post Takeda Amend its Collaboration with Wave Life Sciences to Advance CNS Programs first appeared on PharmaShots.
